English
Back
Open Account
【有獎】2022年IPO投資機會還有哪些？
牛牛新股君
joined discussion · ·

Year-end inventory in 2021: The Hong Kong IPO staged a song of ice and fire, and these sectors still have opportunities.

The 2021 Hong Kong IPO market staged a song of ice and fire.
In the first half of the year,$KUAISHOU-W (01024.HK)$ 、$NH HEALTH (06606.HK)$ 、$ANGELALIGN (06699.HK)$Continuously breaking the record for Hong Kong IPOs, the first-day returns ignited the enthusiasm of the public for new listings.
The Hong Kong stock market in the second half of the year was disappointing, and the subscriptions for IPOs of many star companies were cold, and the stock prices performed unremarkably after listing, extinguishing the fervor for new listings that had lasted for over a year.
On the penultimate trading day of 2021, three new stocks$SENSETIME-W (00020.HK)$$SIRNAOMICS-B (02257.HK)$$CHERVON (02285.HK)$ officially landed on hkex, all closing in the red, drawing a complete end to this year's Hong Kong stock IPOs.
According to the Deloitte report, despite a slight decrease in the number of new stocks and fundraising amounts compared to the peak in 2020, the new stock issuance market remains active.In terms of new stock fundraising amount, hkex ranks fourth globally with the top three being Nasdaq, NYSE, and SSE.
Driven by the return of secondary listings on hkex and innovative companies like biotech firms going public, the fundraising total for the Hong Kong market in 2021 reached a high level in the past decade.Many companies still show interest in listing on the main board, with over 140 companies' listing applications still 'under review.'
According to public data,As of December 24, a total of 93 new stocks were listed on the main board of the Hong Kong Stock Exchange this year, with a total initial public offering of HKD 316.9 billion.Among them, 54 companies are new economy companies, including 33 medical care and biotechnology companies, accounting for nearly 87% of the total amount raised in Hong Kong's initial public offerings during the period.
Looking back on the whole year of 2021, although the overall performance of new stocks in the Hong Kong stock market was not as good as last year, the hot sectors and star IPOs still brought surprises to the market. Let's take a look at the most notable IPO list of this year with the guidance of New Stocks Jun! (The following list data is based on statistics as of December 24, 2021.)
Best first-day performance: Era Angel
The 2021 Hong Kong IPO market staged a song of ice and fire. In the first half of the year,$KUAISHOU-W (01024.HK)$ 、$NH HEALTH (06606.HK)$ 、$ANGELALIGN (06699.HK)$Continuously breaking the record for Hong Kong IPOs, the first-day returns ignited the enthusiasm of the public for new listings. The Hong Kong stock market in the second half of the year was disappointing, and the subscriptions for IPOs of many star companies were cold, and the stock prices performed unremarkably after listing, extinguishing the fervor for new listings that had lasted for over a year. On the penultimate trading day of 2021, three new stocks$SENSETIME-W (00020.HK)$$SIRNAOMICS-B (02257.HK)$$CHERVON (02285.HK)$ officially landed on hkex, all closing in the red, drawing a complete end to this year's Hong Kong stock IPOs. According to a Deloitte report, despite the decrease in the number of new stocks and the amount raised compared to the peak in 2020, the new stock issuance market remains active. In terms of the amount raised by new stocks, HKEX ranks fourth globally, behind NASDAQ, NYSE, and SSE. Driven by the return of secondary listings on HKEX and the IPOs of innovative companies such as biotech firms, the fundraising total in the Hong Kong market in 2021 has reached a relatively high level over the past decade. Many companies still have a keen interest in listing on the main board, with over 140 companies' listing applications still pending...
Era Angel created a myth that is difficult to surpass in the Hong Kong new stock market.
Leading domestic invisible correction company$ANGELALIGN (06699.HK)$In May, it was listed on the Hong Kong Stock Exchange and received unprecedented high attention from the capital market.
In the Futu dark market, Era Angel's intraday highest increase reached 142.6% and ultimately closed at an increase of 112.72%, earning HKD 0.039 million per lot. On the first day of listing, Era Angel continued its impressive performance.It soared 183% in intraday trading, earning HK$63,400 per lot, once again breaking the record for the most profitable new stock in Hong Kong's history.As of the end of the first day of trading, Era Angel closed up 131.79%.With a profit of HK$45,600 per lot, it topped the list of IPO first-day returns in the Hong Kong stock market for 2021.
From the closing price on the first day of trading, there were four new stocks in 2021 that had a profit of over 10,000 yuan per lot, including the first domestic gene testing cancer early screening stock.$NH HEALTH (06606.HK)$ The national-level short video live streaming platform$KUAISHOU-W (01024.HK)$ biopharmaceutical company that is listed in three different locations$HUTCHMED (00013.HK)$The first day of trading was also impressive for the mooer who have subscribed to new stocks. Did you make a profit?
Largest gain on the first day: Sunson International
The 2021 Hong Kong IPO market staged a song of ice and fire. In the first half of the year,$KUAISHOU-W (01024.HK)$ 、$NH HEALTH (06606.HK)$ 、$ANGELALIGN (06699.HK)$Continuously breaking the record for Hong Kong IPOs, the first-day returns ignited the enthusiasm of the public for new listings. The Hong Kong stock market in the second half of the year was disappointing, and the subscriptions for IPOs of many star companies were cold, and the stock prices performed unremarkably after listing, extinguishing the fervor for new listings that had lasted for over a year. On the penultimate trading day of 2021, three new stocks$SENSETIME-W (00020.HK)$$SIRNAOMICS-B (02257.HK)$$CHERVON (02285.HK)$ officially landed on hkex, all closing in the red, drawing a complete end to this year's Hong Kong stock IPOs. According to a Deloitte report, despite the decrease in the number of new stocks and the amount raised compared to the peak in 2020, the new stock issuance market remains active. In terms of the amount raised by new stocks, HKEX ranks fourth globally, behind NASDAQ, NYSE, and SSE. Driven by the return of secondary listings on HKEX and the IPOs of innovative companies such as biotech firms, the fundraising total in the Hong Kong market in 2021 has reached a relatively high level over the past decade. Many companies still have a keen interest in listing on the main board, with over 140 companies' listing applications still pending...
In 2021, there were 5 companies with a first-day increase of over 100%, with the highest increase being$MORIMATSU INTL (02155.HK)$ ，$NH HEALTH (06606.HK)$ 、$KUAISHOU-W (01024.HK)$Yidu Tech and Era Angel closely followed. Due to the overall poor performance of the market, most new stocks this year, after a brief market frenzy, have seen their stock prices fall sharply.
Due to the different costs of each new stock, the highest first-day increase does not necessarily mean substantial earnings. From a long-term perspective, there is no essential relationship between the quality of a company's fundamentals and short-term price increases.
The largest amount raised: Kuaishou-W
The 2021 Hong Kong IPO market staged a song of ice and fire. In the first half of the year,$KUAISHOU-W (01024.HK)$ 、$NH HEALTH (06606.HK)$ 、$ANGELALIGN (06699.HK)$Continuously breaking the record for Hong Kong IPOs, the first-day returns ignited the enthusiasm of the public for new listings. The Hong Kong stock market in the second half of the year was disappointing, and the subscriptions for IPOs of many star companies were cold, and the stock prices performed unremarkably after listing, extinguishing the fervor for new listings that had lasted for over a year. On the penultimate trading day of 2021, three new stocks$SENSETIME-W (00020.HK)$$SIRNAOMICS-B (02257.HK)$$CHERVON (02285.HK)$ officially landed on hkex, all closing in the red, drawing a complete end to this year's Hong Kong stock IPOs. According to a Deloitte report, despite the decrease in the number of new stocks and the amount raised compared to the peak in 2020, the new stock issuance market remains active. In terms of the amount raised by new stocks, HKEX ranks fourth globally, behind NASDAQ, NYSE, and SSE. Driven by the return of secondary listings on HKEX and the IPOs of innovative companies such as biotech firms, the fundraising total in the Hong Kong market in 2021 has reached a relatively high level over the past decade. Many companies still have a keen interest in listing on the main board, with over 140 companies' listing applications still pending...
The top ten Hong Kong IPO projects raised a total of 188.3 billion Hong Kong dollars in 2021, accounting for 53% of the total annual IPO fundraising in Hong Kong. Among them, Kuaishou-W led the way with a fundraising amount of 48.3 billion Hong Kong dollars, becoming the annual fundraising champion.
In terms of sectors, the secondary listings of Chinese concept stocks in Hong Kong have a prominent position in the fundraising ranking, occupying five out of the top ten projects.，$BIDU-SW (09888.HK)$ 、$BILIBILI-W (09626.HK)$ 、$XPENG-W (09868.HK)$ 、$LI AUTO-W (02015.HK)$ The fundraising amounts of these projects all exceed 10 billion Hong Kong dollars.
According to a Deloitte report, nearly 60% of IPO fundraising this year came from 9 super large new stocks.Mainly new economy companies with different equity structures., andThe number of unprofitable biotech IPOs and the funds raised are higher than last year's level.
The highest oversubscription ratio: Nova Health-B
The 2021 Hong Kong IPO market staged a song of ice and fire. In the first half of the year,$KUAISHOU-W (01024.HK)$ 、$NH HEALTH (06606.HK)$ 、$ANGELALIGN (06699.HK)$Continuously breaking the record for Hong Kong IPOs, the first-day returns ignited the enthusiasm of the public for new listings. The Hong Kong stock market in the second half of the year was disappointing, and the subscriptions for IPOs of many star companies were cold, and the stock prices performed unremarkably after listing, extinguishing the fervor for new listings that had lasted for over a year. On the penultimate trading day of 2021, three new stocks$SENSETIME-W (00020.HK)$$SIRNAOMICS-B (02257.HK)$$CHERVON (02285.HK)$ officially landed on hkex, all closing in the red, drawing a complete end to this year's Hong Kong stock IPOs. According to a Deloitte report, despite the decrease in the number of new stocks and the amount raised compared to the peak in 2020, the new stock issuance market remains active. In terms of the amount raised by new stocks, HKEX ranks fourth globally, behind NASDAQ, NYSE, and SSE. Driven by the return of secondary listings on HKEX and the IPOs of innovative companies such as biotech firms, the fundraising total in the Hong Kong market in 2021 has reached a relatively high level over the past decade. Many companies still have a keen interest in listing on the main board, with over 140 companies' listing applications still pending...
In 2021, a total of 7 new stocks received a thousandfold subscription, concentrated in the medical concept sector.
Among them$NH HEALTH (06606.HK)$With an oversubscription ratio of over 4100 times, it became the most popular new stock this year.
Hottest sectors: secondary listings on HKEX, biotech companies
中概股回港潮今年继续加速，2021年全年共有8家在美上市中概股公司完成回港上市。
Among them$HUTCHMED (00013.HK)$ 、$XPENG-W (09868.HK)$ 、$LI AUTO-W (02015.HK)$ 采用双重主要上市的方式登陆港交所，为后续其他海外上市发行人提供了另一种可行的上市途径。
8家公司累计募资97 billion港元，主要集中于可选消费、信息技术和医疗保健等新兴领域。
In terms of the rate of increase, the stock with the highest first-day increase among the secondary listings on HKEX this year is$HUTCHMED (00013.HK)$ , reaching 50.37%, and the least ideal first-day performance is$WB-SW (09898.HK)$ , with a decrease of 7.18%.
The 2021 Hong Kong IPO market staged a song of ice and fire. In the first half of the year,$KUAISHOU-W (01024.HK)$ 、$NH HEALTH (06606.HK)$ 、$ANGELALIGN (06699.HK)$Continuously breaking the record for Hong Kong IPOs, the first-day returns ignited the enthusiasm of the public for new listings. The Hong Kong stock market in the second half of the year was disappointing, and the subscriptions for IPOs of many star companies were cold, and the stock prices performed unremarkably after listing, extinguishing the fervor for new listings that had lasted for over a year. On the penultimate trading day of 2021, three new stocks$SENSETIME-W (00020.HK)$$SIRNAOMICS-B (02257.HK)$$CHERVON (02285.HK)$ officially landed on hkex, all closing in the red, drawing a complete end to this year's Hong Kong stock IPOs. According to a Deloitte report, despite the decrease in the number of new stocks and the amount raised compared to the peak in 2020, the new stock issuance market remains active. In terms of the amount raised by new stocks, HKEX ranks fourth globally, behind NASDAQ, NYSE, and SSE. Driven by the return of secondary listings on HKEX and the IPOs of innovative companies such as biotech firms, the fundraising total in the Hong Kong market in 2021 has reached a relatively high level over the past decade. Many companies still have a keen interest in listing on the main board, with over 140 companies' listing applications still pending...
In addition to the secondary listings of Chinese companies, the number of biotech companies listed on HKEX has also increased further this year.
As of December 24th, a total of 33 medical and biotech companies have landed on HKEX this year, a significant increase from last year, reflecting continued market interest and ecosystem development. The total fundraising amount for biotech companies reached HK$77.7 billion, accounting for approximately 25% of the total fundraising amount in 2021.
Among them, there are a total of 19 unprofitable biotech IPOs, including the popular new stock Siasun Robot&Automation-B.This sector raised a total of HK$37.2 billion, with both the number and the amount raised higher than the level in 2020.
The average first-day price change in this sector was 10.1%, with the best first-day performance being$NH HEALTH (06606.HK)$ On the first day, it rose more than 215%, and the worst performance was $CANBRIDGE-B (01228.HK)$ On the first day, it fell nearly 27%.
The 2021 Hong Kong IPO market staged a song of ice and fire. In the first half of the year,$KUAISHOU-W (01024.HK)$ 、$NH HEALTH (06606.HK)$ 、$ANGELALIGN (06699.HK)$Continuously breaking the record for Hong Kong IPOs, the first-day returns ignited the enthusiasm of the public for new listings. The Hong Kong stock market in the second half of the year was disappointing, and the subscriptions for IPOs of many star companies were cold, and the stock prices performed unremarkably after listing, extinguishing the fervor for new listings that had lasted for over a year. On the penultimate trading day of 2021, three new stocks$SENSETIME-W (00020.HK)$$SIRNAOMICS-B (02257.HK)$$CHERVON (02285.HK)$ officially landed on hkex, all closing in the red, drawing a complete end to this year's Hong Kong stock IPOs. According to a Deloitte report, despite the decrease in the number of new stocks and the amount raised compared to the peak in 2020, the new stock issuance market remains active. In terms of the amount raised by new stocks, HKEX ranks fourth globally, behind NASDAQ, NYSE, and SSE. Driven by the return of secondary listings on HKEX and the IPOs of innovative companies such as biotech firms, the fundraising total in the Hong Kong market in 2021 has reached a relatively high level over the past decade. Many companies still have a keen interest in listing on the main board, with over 140 companies' listing applications still pending...
What other investment opportunities are there for Hong Kong IPOs in 2022?
Although the overall Hong Kong IPO market in 2021 was not satisfactory, it did not dampen the enthusiasm of star companies for listing in Hong Kong. According to the official website of the Hong Kong Exchanges and Clearing Limited (HKEX), There are still over 140 companies whose listing applications are still under review.
Looking ahead to 2022, the return of Chinese concept stocks, the effectiveness of the SPAC listing mechanism, and the resurgence of industry giants are expected to become highlights of the new stock market next year.
With the increasingly mature ecosystem for nurturing innovative and new economy companies, as well as the support of new listing rules for overseas issuers, Hong Kong's market will welcome more dual-primary and secondary listings from Chinese concept stocks in 2022. The listing mechanism for Special Purpose Acquisition Companies (SPACs) will also help attract high-growth companies from the Asia region or privatized Chinese concept stocks to list in the form of SPAC acquisitions.
- Deloitte's "Review of the Mainland China and Hong Kong New Stock Markets in 2021 and Outlook for 2022" report
The return of Chinese concept stocks.
The Hong Kong Exchanges and Clearing Limited (HKEX) recently updated its rules on overseas-listed companies seeking secondary listings in Hong Kong.Starting in 2022, the standards for secondary listings of overseas issuers returning to Hong Kong will be lowered.Analysts believe that the reform of the system may ignite enthusiasm for the secondary listings of Chinese companies listed overseas in Hong Kong, which have complex equity structures and are already considering returning to Hong Kong.
相关阅读：With the relaxation of the listing standards for secondary listings in Hong Kong, the wave of Chinese companies returning to Hong Kong is expected to sweep across a wider range of industries.
The 2021 Hong Kong IPO market staged a song of ice and fire. In the first half of the year,$KUAISHOU-W (01024.HK)$ 、$NH HEALTH (06606.HK)$ 、$ANGELALIGN (06699.HK)$Continuously breaking the record for Hong Kong IPOs, the first-day returns ignited the enthusiasm of the public for new listings. The Hong Kong stock market in the second half of the year was disappointing, and the subscriptions for IPOs of many star companies were cold, and the stock prices performed unremarkably after listing, extinguishing the fervor for new listings that had lasted for over a year. On the penultimate trading day of 2021, three new stocks$SENSETIME-W (00020.HK)$$SIRNAOMICS-B (02257.HK)$$CHERVON (02285.HK)$ officially landed on hkex, all closing in the red, drawing a complete end to this year's Hong Kong stock IPOs. According to a Deloitte report, despite the decrease in the number of new stocks and the amount raised compared to the peak in 2020, the new stock issuance market remains active. In terms of the amount raised by new stocks, HKEX ranks fourth globally, behind NASDAQ, NYSE, and SSE. Driven by the return of secondary listings on HKEX and the IPOs of innovative companies such as biotech firms, the fundraising total in the Hong Kong market in 2021 has reached a relatively high level over the past decade. Many companies still have a keen interest in listing on the main board, with over 140 companies' listing applications still pending...
The SPAC (Special Purpose Acquisition Company) blind box phenomenon has arrived.
In December, the HKEX announced a new listing mechanism for SPACs, accepting applications for SPAC listings starting from January 1, 2022. Charles Li, the Chief Executive of HKEX, expressed the hope that by introducing the SPAC listing mechanism, it will allow experienced and reputable SPAC sponsors to identify emerging and innovative industry companies as acquisition targets, and support the growth and success of promising enterprises.
Ou Zhenxing is expected to have 5 to 10 SPACs next year, which may attract privatized Chinese concept stocks in the United States and high-growth companies in Asia to list in Hong Kong through SPACs.
相关阅读：The Hong Kong Stock Exchange officially introduced SPACs, which will be implemented on January 1st next year. Who will be the first to try it out?
The giants are lurking, and these star IPOs are still waiting to go public.
Affected by the downturn in the Hong Kong stock market, some highly anticipated star companies pressed the pause button on the eve of their IPOs. This includes China's leading spicy snack food company Wei Long and the world's largest duty-free retailer China Tourism Group Duty Free Corporation.
When the market heats up again, these giants will undoubtedly start the new stock feast once more. Which new stock are you waiting for? Feel free to leave a comment in the comment section~
Image source: IPO veteran driver
Conclusion
Some people say that the 2021 Hong Kong stock market's new shares trading year is unfavorable. With the opening of heavyweight guests and the continuous appearance of star companies, it was expected that the new shares trading would be pushed to another climax of madness, but in the end, it ended in a sorry state.
Since the beginning of this year, new shares investors have gradually returned to rationality from enthusiasm, and they have been affected by the sluggish market sentiment. New shares have frequently broken below the IPO price, and some high-quality new shares have also suffered from unjustified suppression.
Nevertheless, the Hong Kong market, where the soil for nurturing the new economy is gradually taking shape, continues to attract more high-quality companies to go public. Looking forward to 2022, it is expected that there will be a new wave of secondary listings on HKEX, with industry giants shining on the stage, SPAC reform, and consecutive listings of star unicorns, all injecting more vitality into the Hong Kong IPO market.
Editor/Aurora
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
Emm
1
Heart
2
Thumbs Up
38
958K Views
Report
Comments (10)
Write a Comment...
10
41
68